HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kerkhofs, P. Articles by Kettmann, R. Search for Related Content PubMed PubMed Citation Articles by Kerkhofs, P. Articles by Kettmann, R. Agricola Articles by Kerkhofs, P. Articles by Kettmann, R.

Long-term protection against bovine leukaemia virus replication in cattle and sheep

Department of Virology, Veterinary and Agrochemical Research Centre, B-1180 Uccle, Belgium¹
Department of Applied Biochemistry and Biology, Faculté Universitaire des Sciences Agronomiques B-5030 Gembloux, Belgium²

Author for correspondence: Pierre Kerkhofs. Fax +32 2 375 09 79. e-mail piker{at}var.fgov.be

In this report, we have evaluated the ability of two different types of live attenuated bovine leukaemia virus (BLV) variants (BLV DX and BLV 6073) to protect cattle and sheep against a heterologous wild-type BLV challenge. Four months after challenge, the protection of the vaccinated animals was effective in contrast to unvaccinated controls. However, long-term protection (18 months after challenge) was observed only in six out of seven animals, one of the vaccinated cattle being infected 12 months after challenge. A second prospective approach investigated the injection of naked plasmid DNA. Two sheep were injected with plasmid DNA encoding the BLV envelope proteins; the challenge virus infection was delayed but could not be completely abrogated. Our results demonstrate that vaccines based on live attenuated viruses and naked DNA injections are able to delay BLV infection, although complete protection cannot be achieved. In addition, our data cast light onto the need to perform long-term vaccination trials because challenge superinfection can occur even after apparent protection for 12 months.

This article has been cited by other articles:

				A. Florins, N. Gillet, M. Boxus, P. Kerkhofs, R. Kettmann, and L. Willems Even Attenuated Bovine Leukemia Virus Proviruses Can Be Pathogenic in Sheep J. Virol., September 15, 2007; 81(18): 10195 - 10200. [Abstract] [Full Text] [PDF]

				A. Mirsaliotis, K. Nurkiyanova, D. Lamb, J. M. Woof, and D. W. Brighty Conformation-Specific Antibodies Targeting the Trimer-of-Hairpins Motif of the Human T-Cell Leukemia Virus Type 1 Transmembrane Glycoprotein Recognize the Viral Envelope but Fail To Neutralize Viral Entry J. Virol., June 1, 2007; 81(11): 6019 - 6031. [Abstract] [Full Text] [PDF]

				L. Lefebvre, V. Ciminale, A. Vanderplasschen, D. D'Agostino, A. Burny, L. Willems, and R. Kettmann Subcellular Localization of the Bovine Leukemia Virus R3 and G4 Accessory Proteins J. Virol., June 27, 2002; 76(15): 7843 - 7854. [Abstract] [Full Text] [PDF]

				M. Reichert, G. H. Cantor, L. Willems, and R. Kettmann Protective effects of a live attenuated bovine leukaemia virus vaccine with deletion in the R3 and G4 genes J. Gen. Virol., April 1, 2000; 81(4): 965 - 969. [Abstract] [Full Text]